Sumitomo PharmaSumitomo Pharma Co., Ltd.4506東証プライム医薬品FY ending Mar 2026, consolidated, IFRS
Out of every ¥100 of sales, about ¥24 is left as operating profit. Revenue changed +13.7% from the prior year, operating profit +272.6%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | 4.3% | —× | — |
| 2023 | — | —× | -6.1% | —× | — |
| 2024 | — | —× | -30.8% | —× | — |
| 2025 | 5.9% | 0.48× | 2.9% | 4.87× | 13.9% |
| 2026 | 23.6% | 0.59× | 13.8% | 3.35× | 46.3% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 560,035 | 555,544 | 314,558 | 398,832 | 453,294 |
| Cost of revenue | — | — | — | 153,437 | 196,401 |
| Gross profit | — | — | — | 245,395 | 256,893 |
| SG&A | — | — | — | 180,605 | 162,557 |
| Operating income | — | — | — | 28,804 | 107,338 |
| Pretax income | 82,961 | -47,920 | -323,114 | 17,611 | 100,344 |
| Income tax | — | — | — | -6,024 | -6,521 |
| Net income attributable to owners | 56,413 | -74,512 | -314,969 | 23,634 | 106,865 |
| Operating margin | — | — | — | 7.2% | 23.7% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥203B | ¥143.5B | ¥29B | ¥23.1B | ¥44.3B |
| Total assets | ¥1.31T | ¥1.13T | ¥907.5B | ¥742.6B | ¥804.6B |
| Net assets | — | — | ¥156.1B | ¥169.5B | ¥292.5B |
| Share capital | — | — | — | ¥22.4B | ¥22.4B |
| Property, plant and equipment | — | — | — | ¥46.6B | ¥44.2B |
| Goodwill | — | — | — | ¥197.4B | ¥211.1B |
| Current assets | — | — | — | ¥253.2B | ¥279.3B |
| Total liabilities | — | — | — | ¥573.1B | ¥512.1B |
| Equity attributable to owners of parent | — | — | — | ¥169.5B | ¥292.5B |
| Retained earnings | — | — | — | ¥46.8B | ¥159B |
| Treasury stock | — | — | — | -¥682M | -¥684M |
EDINET (FSA Japan)
有価証券報告書－第206期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第205期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第203期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第202期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第201期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.